Novo Nordisk (NVO) has named a new head for its U.S. operations as the Ozempic maker faces a steep decline in sales this year amid competition from Eli Lilly (LLY), which has overtaken the Danish pharma giant
Novo adds new U.S. chief amid sales decline
